OmniAb, Inc.

NASDAQ:OABI

Biotechnology

Healthcare
$5.08 +7.88%

+$0.16 today

Market cap
$740.97M
Beta
1.15
P/E (TTM)
-5.2
EPS (TTM)
-$0.42
52W Low $1.30High $2.79

Volume 1.22M

Average 0.67M

OABI Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

OmniAb, Inc.NASDAQ: OABI

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow declines year over year

Q1 FY2026 free cash flow of $5.08M (cash outflow) fell 68.4% year over year, behind the -34.4% change in trailing-twelve-month free cash flow. Sequentially, it fell 10.6% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.

Context

  • Free cash flow amounted to 198.3% of revenue in FY2025, up 40.9 pp from a year earlier.
  • Free cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -68.4% toward the trailing-twelve-month pace of -34.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.08M-10.6% QoQ
Last fiscal yearDec 2025
-$37.02M-10.9% YoY
LTMMar 2026
-$26.02M-34.4% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-68.4%——
1 year-10.9%——
3-year CAGR+21.3%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(37.02M) USD
Year-over-year change
+10.9%

Free Cash Flow vs competitors

How OABI compares with its peers on the latest reported figures

  • OABI's LTM Mar 2026 free cash flow of $26.02M is the smallest of the 4 companies compared; the peer median is $98.51M.
  • Its year-over-year change of -34.4% is the lowest of 4, against a peer median of -1.0%.
  • Free cash flow amounts to 90.0% of revenue for OABI, versus a peer median of 152.7%.
OABI Competitors Peer median
Free Cash Flow for OABI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$152.14M -23.4%+246.3%152.7%
ABSIAbsci CorporationLTM Mar 2026$98.51M +28.3%-1.2%5365.2%
MGNXMacroGenics, Inc.LTM Mar 2026$71.69M -1.0%-2.9%45.6%
OABIOmniAb, Inc.LTM Mar 2026$26.02M -34.4%+21.3%90.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding OABI) $98.51M-1.0%-1.2%152.7%

Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.04M)(22.33M)(50.62M)(62.03M)(64.78M)
Depreciation & Amortization16.25M18.25M19.5M23.58M21.75M
Deferred Income Tax(7.33M)(6.42M)(12.54M)(9.04M)(1.53M)
Stock-Based Compensation15.07M18.32M24.82M21.5M15.82M
Change in Working Capital(2.63M)(10.83M)24.87M(10.17M)(4.95M)
Accounts Receivables6.02M(12.74M)26.9M(625K)189K
Inventory(1.51M)0000
Accounts Payables1.51M15.07M920K(2.41M)(231K)
Other Working Capital(8.65M)(13.16M)(2.95M)(7.14M)(4.91M)
Other Non-Cash Items9K(572K)(3.68M)(3.5M)(4.3M)
Operating Cash Flow(5.67M)(3.59M)2.35M(39.66M)(36.46M)
Capital Expenditures(4.07M)(17.17M)(1.64M)(1.88M)(565K)
Acquisitions (Net)00000
Purchases of Investments0(54.78M)(112.62M)(40.29M)(46.86M)
Sales of Investments1.27M70K100.32M80.45M50.89M
Other Investing Activities(1.22M)(1.44M)(4.44M)(400K)3M
Investing Cash Flow(4.03M)(73.31M)(18.38M)37.88M6.47M
Debt Repayment00000
Common Stock Issued096.24M011.37M28.36M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.7M14.5M(892K)1.65M(450K)
Financing Cash Flow9.7M110.74M(892K)13.02M27.91M
Effect of Forex Changes00000
Net Change in Cash033.84M(16.92M)11.24M(2.07M)
Free Cash Flow(9.74M)(20.76M)703K(41.54M)(37.02M)

OmniAb, Inc.

NASDAQ:OABI

Intrinsic Alpha fair value

Locked

Current Price

$5.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.